Vanda Pharmaceuticals Inc.
A Washington, D.C.-based biopharmaceutical company that develops medicines for brain and nervous-system conditions. Its products include Hetlioz, a treatment for a rare sleep disorder in which totally blind people's internal body clocks drift because they cannot perceive light, and Fanapt, an antipsychotic for schizophrenia. Founded in 2003 by a Greek-American scientist who worked on the Human Genome Project, the company takes its name from the Vanda, a genus of orchids.
Granted 1.96M · Bought 110.0K · Sold 485.6K
Granted 441.6K · Sold 92.2K
Granted 447.9K · Bought 2.0K · Sold 110.9K
Granted 440.4K · Sold 119.2K
Granted 348.1K · Sold 73.7K
Granted 165.7K · Sold 6.5K
Granted 152.0K
Granted 150.7K
Granted 165.1K · Sold 30.0K
Granted 169.8K · Sold 40.3K
Granted 98.7K
Granted 12.1K · Sold 16.8K
Granted 15.0K · Sold 6.4K
Granted 80.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Polymeropoulos Mihael HristosPresident and CEO, Director, Chairman of the Board · 35 transactions | +121.5% | 2.70M | 1.96M | 110.0K | 485.6K |
| Birznieks GuntherSVP, Business Development · 14 transactions | +187.8% | 494.2K | 441.6K | — | 92.2K |
| Moran Kevin PatrickSVP, CFO & Treasurer · 21 transactions | — | 412.6K | 447.9K | 2.0K | 110.9K |
| Williams TimothySVP & General Counsel · 16 transactions | +353.6% | 377.4K | 440.4K | — | 119.2K |
| Wijkstrom JoakimSVP, Chief Marketing Officer · 14 transactions | +347.3% | 333.5K | 348.1K | — | 73.7K |
| Dugan Richard WDirector · 7 transactions | +265.8% | 219.1K | 165.7K | — | 6.5K |
| Chrousos PhaedraDirector · 5 transactions | +1176.2% | 164.9K | 152.0K | — | — |
| Ward Anne SempowskiDirector · 5 transactions | +1506.7% | 160.7K | 150.7K | — | — |
| Honore TageDirector · 6 transactions | — | 135.1K | 165.1K | — | 30.0K |
| Mitchell Stephen RayDirector · 13 transactions | +1124.6% | 112.8K | 169.8K | — | 40.3K |
| Duncan Charles CliffDirector · 2 transactions | — | 98.7K | 98.7K | — | — |
| Jones Aranthan IIChief Corp. Affairs Officer · 3 transactions | -5.4% | 82.0Kas of Sep 2021 | 12.1K | — | 16.8K |
| Watkins ThomasDirector · 2 transactions | +27.5% | 69.5Kas of Jun 2022 | 15.0K | — | 6.4K |
| McGuire Daniel PatrickSVP, GC and Secretary · 1 transaction | — | 6.0K | 80.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -869.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.